Biobizkaia
Centro de investigación
Hôpital Notre-Dame
Montreal, CanadáPublicaciones en colaboración con investigadores/as de Hôpital Notre-Dame (8)
2022
-
Confirmed disability progression as a marker of permanent disability in multiple sclerosis
European Journal of Neurology, Vol. 29, Núm. 8, pp. 2321-2334
2020
-
Risk of secondary progressive multiple sclerosis: A longitudinal study
Multiple Sclerosis Journal, Vol. 26, Núm. 1, pp. 79-90
2019
-
Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study
European Journal of Neurology, Vol. 26, Núm. 2, pp. 363-370
2018
-
Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis
Multiple Sclerosis Journal, Vol. 24, Núm. 5, pp. 642-652
2017
-
Towards personalized therapy for multiple sclerosis: Prediction of individual treatment response
Brain, Vol. 140, Núm. 9, pp. 2426-2443
-
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study
The Lancet Neurology, Vol. 16, Núm. 4, pp. 271-281
2016
-
Defining secondary progressive multiple sclerosis
Brain, Vol. 139, Núm. 9, pp. 2395-2405
2015
-
Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis
Annals of Neurology, Vol. 77, Núm. 3, pp. 425-435